Dossier assessment
Serplulimab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Serplulimab (NSCLC) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Serplulimab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
First-line treatment of non-squamous non-small cell lung carcinoma (NSCLC), with no epidermal growth factor receptor, anaplastic lymphoma kinase or c-ros oncogene 1 aberrations, in adult patients who have locally advanced NSCLC and are not candidates for surgery or radiotherapy, or who have metastatic NSCLC
- Patients with programmed cell death-ligand 1 (PD-L1) expression on ≥50% of tumour cells: added benefit not proven
- Patients with PD-L1 expression on <50% of tumour cells: added benefit not proven
Project details
- Project no.
- A26-89
- Commission
- Commission awarded on 23.07.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-89
Connected Projects
-
Dossier assessment
Serplulimab (small cell lung cancer, first line) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Serplulimab (squamous NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Serplulimab (small cell lung cancer, in combination with carboplatin and etoposide, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed